Track 04 of 9
GI Oncology
Colorectal, gastric, pancreatic and esophageal cancers.
GI oncology is being reshaped by molecularly stratified care: ctDNA-guided adjuvant decisions in stage II/III colon cancer (DYNAMIC, GALAXY), MSI-high tumors responding to neoadjuvant dostarlimab and pembrolizumab (with watch-and-wait emerging in rectal cancer), and HER2-positive gastric/GEJ disease driven by trastuzumab deruxtecan and zolbetuximab (CLDN18.2). Pancreatic cancer remains the hardest target, but mRNA neoantigen vaccines, KRAS G12C/G12D inhibitors, and FOLFIRINOX intensification offer incremental gains. Sessions also cover Barrett’s surveillance with WATS3D and AI, and cholangiocarcinoma FGFR2/IDH1-targeted therapy.
Focus areas
- ctDNA-guided adjuvant therapy in colon cancer (DYNAMIC, GALAXY)
- Neoadjuvant immunotherapy in MMR-deficient rectal and colon cancer
- HER2 and CLDN18.2 in gastric/GEJ: trastuzumab deruxtecan, zolbetuximab
- Pancreatic cancer: KRAS G12C/G12D inhibitors and mRNA neoantigen vaccines
- Barrett’s esophagus surveillance: WATS3D, AI and EET
- Cholangiocarcinoma: FGFR2 fusions, IDH1 mutations, targeted therapy
- Hereditary GI cancer syndromes and universal MMR screening